Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Exclusion Criteria

• •Patients with more than one prior regimen of chemotherapy or prior regimen that did not contain a platinum agent. Note: Patient who stopped prior therapy due to toxicity or had less than 2 cycles of platinum based therapy would not be eligible for the phase II portion of this study.
• •Prior chemotherapy regimen containing irinotecan.
• •Active secondary malignancy.
• •Unstable or progressive brain metastases.
• •Prior history of radiation therapy to \> 25% of the bone marrow.
• •Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
• •Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation, chemotherapy).